These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 36250028)

  • 1. Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands.
    de Jongh FE; Efe R; Herrmann KH; Spoorendonk JA
    Int J Breast Cancer; 2022; 2022():5909724. PubMed ID: 36250028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands.
    Simons MJHG; Machielsen PM; Spoorendonk JA; Ignacio T; Drost PB; Jacobs T; de Jongh FE
    J Med Econ; 2024; 27(1):445-454. PubMed ID: 38436289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
    Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
    Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The budget impact of utilizing the Oncotype DX Breast Recurrence Score test from a US healthcare payer perspective.
    Berdunov V; Laws E; Cuyun Carter G; Luo R; Russell C; Campbell S; Force J; Abdou Y
    J Med Econ; 2023; 26(1):973-990. PubMed ID: 37466220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer.
    Browne IM; McLaughlin RA; Weadick CS; O'Sullivan S; McSorley LM; Hadi DK; Millen SJ; Higgins MJ; Crown JP; Prichard RS; McCartan DP; Hill AD; Connolly RM; Noonan SA; O'Mahony D; Murray C; O'Hanlon-Brown C; Hennessy BT; Quinn CM; Kelly CM; O'Reilly S; Morris PG; Walshe JM
    Breast Cancer Res Treat; 2024 Oct; ():. PubMed ID: 39365509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budget Impact of the Oncotype DX Breast Recurrence Score
    Lux MP; Minartz C; Müller-Huesmann H; Sandor MF; Radeck-Knorre S; Neubauer AS
    Breast Care (Basel); 2024 Feb; 19(1):27-33. PubMed ID: 38384494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budget impact of the Oncotype DX® test compared to other gene expression tests in patients with early breast cancer in Germany.
    Lux MP; Minartz C; Müller-Huesmann H; Sandor MF; Herrmann KH; Radeck-Knorre S; Neubauer AS
    Cancer Treat Res Commun; 2022; 31():100519. PubMed ID: 35093682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group*
    Genet Med; 2016 Aug; 18(8):770-9. PubMed ID: 26681310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score
    Berdunov V; Cuyun Carter G; Laws E; Luo R; Russell CA; Campbell S; Abdou Y; Force J
    Clinicoecon Outcomes Res; 2024; 16():471-482. PubMed ID: 38855430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model.
    Yang M; Rajan S; Issa AM
    Cancer; 2012 Oct; 118(20):5163-70. PubMed ID: 22359236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer.
    Berdunov V; Millen S; Paramore A; Hall P; Perren T; Brown R; Griffin J; Reynia S; Fryer N; Longworth L
    J Med Econ; 2022; 25(1):591-604. PubMed ID: 35416089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic Impact of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in France.
    Katz G; Romano O; Foa C; Vataire AL; Chantelard JV; Hervé R; Barletta H; Durieux A; Martin JP; Salmon R
    PLoS One; 2015; 10(6):e0128880. PubMed ID: 26086912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in a Middle-Income Country, Turkey: Results of a Prospective Multicenter Study.
    Özmen V; Çakar B; Gökmen E; Özdoğan M; Güler N; Uras C; Ok E; Demircan O; Işıkdoğan A; Saip P
    Eur J Breast Health; 2019 Jul; 15(3):183-190. PubMed ID: 31312795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budget impact analysis of gene expression tests to aid therapy decisions for breast cancer patients in Germany.
    Lux MP; Nabieva N; Hildebrandt T; Rebscher H; Kümmel S; Blohmer JU; Schrauder MG
    Breast; 2018 Feb; 37():89-98. PubMed ID: 29128582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline.
    Blanchette P; Sivajohanathan D; Bartlett J; Eisen A; Feilotter H; Pezo R; Turashvili G; Williams P
    Curr Oncol; 2022 Apr; 29(4):2599-2615. PubMed ID: 35448187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the U.K.
    Holt S; Bertelli G; Humphreys I; Valentine W; Durrani S; Pudney D; Rolles M; Moe M; Khawaja S; Sharaiha Y; Brinkworth E; Whelan S; Jones S; Bennett H; Phillips CJ
    Br J Cancer; 2013 Jun; 108(11):2250-8. PubMed ID: 23695023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic signature to guide adjuvant chemotherapy treatment decisions for early breast cancer patients in France: a cost-effectiveness analysis.
    Curtit E; Bellanger MM; Nerich V; Hequet D; Frenel JS; Cristeau O; Rouzier R
    Front Oncol; 2023; 13():1191943. PubMed ID: 37427133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center.
    Thibodeau S; Voutsadakis IA
    Eur J Breast Health; 2019 Jul; 15(3):163-170. PubMed ID: 31312792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Economic assessment of the routine use of Oncotype DX® assay for early breast cancer in Franche-Comte region].
    Nerich V; Curtit E; Bazan F; Montcuquet P; Villanueva C; Chaigneau L; Cals L; Méneveau N; Dobi E; Altmotlak H; Algros MP; Choulot MJ; Nallet G; Limat S; Mansion S; Pivot X
    Bull Cancer; 2014; 101(7-8):681-9. PubMed ID: 25091650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.